Flex Pharma (FLKS) Reports Q4 Loss of $0.46/Share

Flex Pharma (NASDAQ: FLKS) reported Q4 EPS of ($0.46), versus ($0.48) reported last year. Revenue for the quarter came in at $283 thousand, versus $291 thousand reported last year.

Financial Guidance

Based on its current operating plans and cash, cash equivalents and marketable securities position, Flex Pharma expects to have sufficient capital to fund its operations to mid 2019.

For earnings history and earnings-related data on Flex Pharma (FLKS) click here.

You May Also Be Interested In

• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Baidu (BIDU) Misses Q2 EPS by 262c, misses on revenue
• Citi upgrades Bath & Body Works to Buy with $25 price target